Topics

Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims

07:36 EDT 12 Jul 2019 | BioPharmaDive

The setback in high-risk pre-symptomatic patients raises questions over use of anti-beta amyloid agents, even in a preventive setting.

Original Article: Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims

NEXT ARTICLE

More From BioPortfolio on "Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims"

Quick Search

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...